Urinary Tumor Markers for Bladder Cancer AHS - G2125
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical policy on the use, validity, and recommended role of urine-based tumor marker tests for diagnosis and surveillance of bladder/urothelial cancer for providers and payers.
CPT code 0613U was added to the Billing/Coding section effective 1/1/2026.
CPT codes 0012M, 0013M, 0363U, 0420U, 0452U, 0465U, 0549U, and 0613U were removed from this policy and will be managed under policy Liquid Biopsy AHS - G2054.
Coverage criteria language updated to clarify reimbursement is allowed 'as an adjunct to cystoscopy, urinary biomarker' instead of prior phrasing.
Coverage Criteria for Urinary Tumor Markers
General guideline-based stance
Covered when used in accordance with published guidelines and only as an adjunct to cystoscopic evaluation.
Reflects guidance from NCCN, AUA/SUFU, AUA/SUO, and EAU.
Permitted adjunctive uses
Permitted adjunctive uses supported by guideline statements include:
AUA/SUO and AUA guidance allow biomarkers for BCG response assessment and to clarify equivocal cytology; NCCN supports adjunctive use in surveillance of high-risk NMIBC.
When markers are not recommended
Situations where routine use is discouraged or not recommended:
Statements based on AUA/SUFU and EAU guideline conclusions that markers cannot supplant cystoscopic diagnosis and are not recommended for routine initial evaluation.
When Covered (summary)
Summary of coverage intent when medical criteria and guideline-based indications are met:
Policy updates clarified wording to emphasize adjunctive use with cystoscopy and urinary cytology; coverage remains contingent on meeting medical criteria and documentation requirements.
The European Association of Urology (EAU) concludes that cystoscopy is necessary for the diagnosis of bladder cancer and that there is no known urinary marker specific for the diagnosis of invasive bladder cancer. The EAU further states that urinary molecular marker tests cannot replace cystoscopy in routine practice, although knowledge of positive results from some markers may inform follow-up cystoscopy.
Policy history shows prior wording that explicitly disallowed reimbursement for “all other urinary biomarkers, including but not limited to quantitative mRNA (Cxbladder),” but that statement was subsequently removed. Implementation notes document iterative edits to the When Covered and When Not Covered language over multiple updates, including additions and later removals of specific billing codes in the Billing/Coding section.
Routine population screening for bladder cancer in asymptomatic adults is not supported — the USPSTF assigned a grade I (insufficient evidence) and the National Cancer Institute found inadequate evidence that screening affects mortality. Guidelines from the AUA/SUO and other societies consistently state that urinary biomarkers should not replace cystoscopy for surveillance or initial evaluation; biomarkers may have limited adjunctive roles but have not demonstrated a benefit as a screening tool.
Earlier policy text labeled some non‑specified uses of urinary biomarkers as investigational or not reimbursable; subsequent revisions removed that blanket investigational phrasing and adjusted specific test-level exclusions as the billing/coding listings changed. The implementation history documents these revisions and the removal of the prior categorical exclusion language.
Billing and Coding
| 0012M | formerly listed; later removed |
| 0013M | formerly listed; later removed |
| 0363U | added 12/30/22; later removed |
| 0365U | added 4/18/23 |
| 0366U | added 4/18/23 |
| 0367U | added 4/18/23 |
| 0420U | added 5/15/24; later removed |
| 0452U | added 9/04/24; later removed |
| 0465U | added 9/04/24; later removed |
| 0549U | added 4/1/25; later removed |
Provider Actions and Requirements
Applicable billing codes — presence does not guarantee reimbursement
This policy may apply to the following codes: 86294, 86316, 86386, 88120, 88121, 88346, 88350, 0365U, 0366U, 0367U. Inclusion of a code in this section does not guarantee that it will be reimbursed; see BCBSNC Administrative Policies for reimbursement guidance.
Verify member contract for benefits and eligibility
This medical policy is not an authorization, certification, explanation of benefits, or a contract; benefits and eligibility are determined by the member's group contract and subscriber certificate in effect at the time services are rendered.
- Verify member benefits and eligibility with the payer prior to ordering tests
- Medical policy application occurs after benefits/eligibility determination
Codes listed do not by themselves establish coverage
Inclusion of CPT/HCPCS codes in this policy indicates the policy may apply to those tests, but does not itself establish coverage; BCBSNC may review medical records to determine medical necessity for claims submitted under these codes.
- Do not assume coverage solely because a code appears in this policy
- Expect clinical review if medical necessity is unclear
Follow policy 'When Covered' criteria for reimbursement
Reimbursement is allowed only when the service meets the policy's 'When Covered' criteria; providers must follow the policy criteria (e.g., adjunctive use with cystoscopy and urinary cytology) to support reimbursement.
- Order and document testing consistent with the policy's 'When Covered' requirements
- Coverage intent unchanged despite wording edits — follow current criteria text
Provide complete documentation when medical records are requested
If BCBSNC requests medical records to determine medical necessity, include all specific clinical information needed to make the determination; letters of support or explanation are useful but are not sufficient unless they contain the required clinical details.
- Provide complete medical records documenting indications, prior diagnostic findings (e.g., cystoscopy, cytology), and rationale for adjunctive biomarker testing
- Include dates, procedures, and relevant pathology/cytology results
Medical records may be requested — letters alone often insufficient
BCBSNC may request medical records for determination of medical necessity; letters alone are often insufficient unless they include all specific information needed for the review.
- Anticipate requests for full chart documentation when submitting claims for urinary tumor markers
- Ensure supporting documentation (procedures, test results, clinical notes) accompanies requests or appeals
Code inclusion does not guarantee reimbursement — medical records may be requested
Inclusion of a code in the policy's coding list does not guarantee reimbursement; BCBSNC may still request medical records and deny payment if medical necessity is not established.
- Do not rely solely on code inclusion when seeking reimbursement
- Be prepared to supply clinical documentation to support medical necessity
Some codes are managed under Liquid Biopsy policy (G2054) — verify correct policy
Certain CPT codes for urinary biomarker testing have been moved to the Liquid Biopsy AHS policy (G2054); submitting those codes under this policy may result in denial or require review under the other policy.
Background and Clinical Context
Urine‑based molecular and protein tumor marker tests generally show higher sensitivity but lower specificity than cytology, particularly for detecting high‑grade disease. Major guideline bodies (AUA/SUO, EAU, NCCN) agree that markers should not replace cystoscopy for diagnosis or surveillance, though some markers may be used as adjuncts — for example, to assess response to intravesical BCG or to adjudicate equivocal cytology (e.g., UroVysion FISH, ImmunoCyt).
Definitions of Tests and Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.